Part of this data was also recently presented at the 2015 American Academy of Neurology Annual Meeting in Washington, DC. by ISCO's chief scientific officer, Ruslan Semechkin, Ph.D. and is another example of how ISCO is leading the way in finding a novel new approach to treating this debilitating disease. We look
forward to reporting progress from our own Parkinson’s disease clinical trial
which we are expecting to begin as soon as we receive regulatory
approval.
The full article can be accessed here.
|